UBS has issued a research report stating that Ollin, a partner of Innovent Bio (HK: 01801), will be acquired by Johnson & Johnson (NYSE: JNJ), with the core Phase 3 asset IBI/OLN324 (Ang2/VEGF) set to be incorporated into Johnson & Johnson's pipeline. The bank holds a positive view on this development and maintains a "Buy" rating on Innovent Bio with a target price of HK$135.3.
The bank noted that the transaction affirms Innovent Bio's strength in ophthalmology R&D, including a upfront payment of US$2.2 billion and up to US$1.125 billion in milestone payments. The Phase 1b clinical data for IBI/OLN324 in wAMD/DME is positive relative to faricimab. Blackstone will pay Johnson & Johnson US$750 million to fully fund the Phase 3 clinical trial of OLN324, in exchange for certain milestones and single-digit royalties.
Comments